Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V. Negrão, Sandip Pravin Patel, Michael J. Dennis et al.|Cancer Discovery|2023Cited by 181
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancerGiannis Mountzios, Petros Christopoulos, Epaminontas Samantas et al.|ESMO Open|2021Cited by 93
Loss of SOX2 expression induces cell motility via vimentin up‐regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinomaPilar Bayo, Jochen Heß, Adriana Jou et al.|Molecular Oncology|2015Cited by 69
Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in GermanyAlbrecht Stenzinger, Verena I. Gaidzik, Anders Edsjö et al.|Seminars in Cancer Biology|2021Cited by 38
Health Care Infrastructure for Financially Sustainable Clinical GenomicsJochen K. Lennerz, A. John Iafrate, Heather M. McLaughlin et al.|Journal of Molecular Diagnostics|2016Cited by 22